{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:38:13Z","timestamp":1768264693820,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.pharma.2024.07.007","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T15:48:08Z","timestamp":1722354488000},"page":"1134-1149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of cilnidipine-loaded self-micro-emulsifying drug delivery system (SMEDDS) by quantification of comparative pharmacokinetic parameters using validated LC-ESI-MS\/MS bioanalytical method and pharmacodynamic assessment"],"prefix":"10.1016","volume":"82","author":[{"given":"Kumar","family":"Anand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallab","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samit","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudranil","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Adil","family":"Shaharyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avishek","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soumya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subhabrata","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manas","family":"Bhowmik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2162-5061","authenticated-orcid":false,"given":"Sanmoy","family":"Karmakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharma.2024.07.007_bib0145","first-page":"95","article-title":"Cilnidipine: next generation calcium channel blocker","volume":"64","author":"Shete","year":"2016","journal-title":"J Assoc Physicians India"},{"issue":"6","key":"10.1016\/j.pharma.2024.07.007_bib0150","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1291\/hypres.27.379","article-title":"Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases","volume":"27","author":"Kojima","year":"2004","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.pharma.2024.07.007_bib0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.diabres.2012.01.024","article-title":"Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria","volume":"97","author":"Fukumoto","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.pharma.2024.07.007_bib0160","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/jch.12412","article-title":"Effects of the N\/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE Study)","volume":"16","author":"Uchida","year":"2014","journal-title":"J Clin Hypertens"},{"issue":"2","key":"10.1016\/j.pharma.2024.07.007_bib0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1755-5922.2009.00079.x","article-title":"Cilnidipine: a new generation Ca2+ channel blocker with inhibitory action on sympathetic neurotransmitter release","volume":"27","author":"Takahara","year":"2009","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.pharma.2024.07.007_bib0170","doi-asserted-by":"crossref","first-page":"101303","DOI":"10.1016\/j.jddst.2019.101303","article-title":"Cilnidipine loaded transfersomes for transdermal application: formulation optimization, in-vitro and in-vivo study","volume":"54","author":"Khatoon","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.pharma.2024.07.007_bib0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jddst.2017.02.002","article-title":"Formulation and evaluation of self-emulsifying drug delivery system for nimodipine, a BCS class II drug","volume":"39","author":"Prajapat","year":"2017","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"10.1016\/j.pharma.2024.07.007_bib0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2015.09.009","article-title":"Development of self-emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity","volume":"495","author":"Jannin","year":"2015","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.pharma.2024.07.007_bib0185","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/10717544.2014.896058","article-title":"Self-microemulsifying drug delivery system (SMEDDS)\u00a0\u2013\u00a0challenges and road ahead","volume":"22","author":"Dokania","year":"2015","journal-title":"Drug Deliv"},{"issue":"2","key":"10.1016\/j.pharma.2024.07.007_bib0190","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2018016710","article-title":"Lipids and surfactants: the inside story of lipid-based drug delivery systems","volume":"35","author":"Pandey","year":"2018","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"6","key":"10.1016\/j.pharma.2024.07.007_bib0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","article-title":"Oral lipid-based drug delivery systems\u00a0\u2013\u00a0an overview","volume":"3","author":"Kalepu","year":"2013","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.pharma.2024.07.007_bib0200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.21276\/apjhs.2022.9.1.05","article-title":"Formulation development, optimization, and characterization of cilnidipine-loaded self-microemulsifying drug delivery system","volume":"9.1","author":"Anand","year":"2022","journal-title":"Asian Pac J Health Sci"},{"key":"10.1016\/j.pharma.2024.07.007_bib0205","series-title":"Use of Internal Standards in LC-MS Bioanalysis. Handbook of LC-MS Bioanalysis","author":"Tan","year":"2013"},{"key":"10.1016\/j.pharma.2024.07.007_bib0210","series-title":"Bioanalytical method validation guidance for industry","year":"2018"},{"issue":"8","key":"10.1016\/j.pharma.2024.07.007_bib0215","doi-asserted-by":"crossref","first-page":"865","DOI":"10.4155\/bio.12.44","article-title":"European Medicines Agency guideline on bioanalytical method validation: what more is there to say?","volume":"4","author":"Smith","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pharma.2024.07.007_bib0220","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.colsurfb.2013.12.016","article-title":"Nanoemulsion strategy for olmesartanmedoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats","volume":"115","author":"Gorain","year":"2014","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"8","key":"10.1016\/j.pharma.2024.07.007_bib0225","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/03639045.2019.1607868","article-title":"Design and development of a self-microemulsifying drug delivery system of olmesartanmedoxomil for enhanced bioavailability","volume":"45","author":"Komesli","year":"2019","journal-title":"Drug Dev Ind Pharm"},{"key":"10.1016\/j.pharma.2024.07.007_bib0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jddst.2017.02.002","article-title":"Formulation and evaluation of self-emulsifying drug delivery system for nimodipine, a BCS class II drug","volume":"39","author":"Prajapat","year":"2017","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5 Suppl.","key":"10.1016\/j.pharma.2024.07.007_bib0235","first-page":"I2","article-title":"Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease","volume":"13","author":"Stamler","year":"1989","journal-title":"Hypertension"},{"issue":"12_Pt_1","key":"10.1016\/j.pharma.2024.07.007_bib0240","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ajh\/5.12.919","article-title":"Sustained hypertension in the rat induced by chronic blockade of nitric oxide production","volume":"5","author":"Johnson","year":"1992","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.pharma.2024.07.007_bib0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.22.1.49","article-title":"Salt-induced increase in arterial pressure during nitric oxide synthesis inhibition","volume":"22","author":"Salazar","year":"1993","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.pharma.2024.07.007_bib0250","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1179\/1351000211Y.0000000009","article-title":"Antihypertensive and antioxidant potential of vanillic acid, a phenolic compound in L-NAME-induced hypertensive rats: a dose-dependence study","volume":"16","author":"Kumar","year":"2011","journal-title":"Redox Report"},{"issue":"7","key":"10.1016\/j.pharma.2024.07.007_bib0255","first-page":"4152","volume":"13","year":"2015","journal-title":"Efsa J"},{"key":"10.1016\/j.pharma.2024.07.007_bib0260","unstructured":"Baghdadi H. Development of paediatric dosage forms of furosemide using the problem structuring method of morphological analysis. 2016. Available from: http:\/\/repository.londonmet.ac.uk\/1148\/"},{"key":"10.1016\/j.pharma.2024.07.007_bib0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.fct.2014.06.028","article-title":"A review of the nonclinical safety of Transcutol\u00ae, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient","volume":"72","author":"Sullivan","year":"2014","journal-title":"Food Chem Toxicol"},{"issue":"4","key":"10.1016\/j.pharma.2024.07.007_bib0270","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/bcp.15642","article-title":"High-dose insulin should NOT be used without vasopressors in calcium channel blocker toxicity","volume":"89","author":"Rietjens","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharma.2024.07.007_bib0275","doi-asserted-by":"crossref","first-page":"348","DOI":"10.4103\/0253-7613.132202","article-title":"Cilnidipine induced ankle edema","volume":"46","author":"Annil","year":"2014","journal-title":"Ind J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2024.07.007_bib0280","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40360-018-0198-1","article-title":"A case report of clonidine induced syncope: a review of central actions of an old cardiovascular drug","volume":"19","author":"Sandweiss","year":"2018","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450924001068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T17:48:28Z","timestamp":1729705708000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450924001068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0003450924001068"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2024.07.007","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of cilnidipine-loaded self-micro-emulsifying drug delivery system (SMEDDS) by quantification of comparative pharmacokinetic parameters using validated LC-ESI-MS\/MS bioanalytical method and pharmacodynamic assessment","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2024.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}